Expert view: Early product characterisation mitigates risks in biologics development
Developers of small molecule pharmaceuticals perform a battery of analytical tests before early clinical trials.
List view / Grid view
Articles
Expert view: How automation can improve cell stability and productivity in cell line development
During cell line development, key attributes such as cell productivity, stability and monoclonality are required before progressing cells for manufacturing.
Genomic assays: on the brink of revolutionising human healthcare
Detailed knowledge of the human genome can provide us with extensive information about the causes of disease and how patients will respond to treatments. In this article, Pushpanathan Muthuirulan explores the concept of genetic testing and the potential for pharmacogenomic testing to transform healthcare.
In vitro platforms for de-risking nephrotoxicity during drug development
If not correctly assessed, drug candidates with undesirable safety issues may progress through clinical development, resulting in costly failures later in the development process. Given that many drugs fail in clinical trials due to nephrotoxicity, this article describes the importance of understanding kidney transporter function in drug development, how current…
Expert view: Are you ready for next generation therapeutic antibodies?
Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.
Expert view: Targeting the cGAS-STING pathway with a new Transcreener HTS assay
DNA in the cytoplasm is an indicator of microbial infection, serving as a danger signal and resulting in induction of an innate immune response via the cyclic GAMP synthase (cGAS)/STING (Stimulator of INterferon-sensitive Genes) pathway.
Pooling research and development resources to tackle emerging threats
Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.
TCR therapy – an attractive alternative to CAR T
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
Expert view: The path to the high-hanging fruit: access to greater diversity and rapid down-selection
Therapeutic monoclonal antibodies are proven and effective treatment options but many of the ‘low-hanging fruit’ therapeutics have already been identified.
Lab Automation In-Depth Focus 2020
In this in-depth focus are features on the best data management options currently available and how the future of drug discovery will be connected and fully automated.
Informatics In-Depth Focus 2020
The articles in this in-depth focus explain how informatics aids in the development of genomic research and outline the next steps for AI to progress in pharma.
Antibodies In-Depth Focus 2020
This In-Depth Focus includes articles on antibodies as a treatment for COVID-19, the importance of understanding every aspect of an ADC and the potential of antibodies as a targeted cancer therapeutic.
Assays In-Depth Focus 2020
Included in this In-Depth Focus are articles on why human tissue models are best for testing nephrotoxicity and how genetic and pharmacogenomic testing can improve healthcare options.
Drug Target Review – Issue 1 2020
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
Targeted protein degradation: the next wave of therapeutics
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.
